Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-6-1
|
pubmed:abstractText |
We studied the early phase after 5/6 nephrectomy in Munich-Wistar rats to determine whether treatment with angiotensin II receptor antagonist (AIIRA) modulates the expression of platelet-derived growth factor (PDGF) mRNA and its protein among the glomeruli which are undergoing progressive hypertrophy and sclerosis. Average PDGF-B immunohistochemistry staining score (IHS, 0 to 3 scale) in glomeruli and PDGF-B chain mRNA from kidneys were both increased in 5/6 nephrectomy rats (N = 6) versus age-matched normal (N = 5) at week 4, when glomeruli were at early stages of sclerosis (IHS, 0.81 +/- 0.12 vs. 0.19 +/- 0.05; sclerosis index, S.I., 0 to 4 scale: 0.41 +/- 0.04 vs. 0.05 +/- 0.01, both P < 0.05). AIIRA (80 mg/liter drinking water, N = 6) started at time of 5/6 nephrectomy prevented the development of sclerosis (S.I. 0.08 +/- 0.03) and decreased PDGF-B protein (IHS 0.22 +/- 0.08, both P = NS vs. normal), and PDGF-B chain mRNA. In contrast, triple therapy (TRX; hydralazine, reserpine and hydrochlorothiazide, N = 5) in doses which controlled systemic blood pressure resulted in intermediate level of glomerulosclerosis at this early time point of progressive injury. Concurrently, TRX failed to affect the expression of PDGF-B protein (IHS 0.86 +/- 0.19) or its mRNA expression. The PDGF-B distribution was not uniform amongst the glomeruli with varying stages of sclerosis. There was a strong correlation in individual glomeruli of increased PDGF-B staining with early sclerotic changes (P < 0.01), with the disappearance of this correlation in glomeruli with advanced sclerosis.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet-Derived Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0085-2538
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
131-9
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:7731138-Angiotensin II,
pubmed-meshheading:7731138-Angiotensin Receptor Antagonists,
pubmed-meshheading:7731138-Animals,
pubmed-meshheading:7731138-Blood Pressure,
pubmed-meshheading:7731138-Body Weight,
pubmed-meshheading:7731138-Gene Expression,
pubmed-meshheading:7731138-Glomerulosclerosis, Focal Segmental,
pubmed-meshheading:7731138-Immunoenzyme Techniques,
pubmed-meshheading:7731138-In Situ Hybridization,
pubmed-meshheading:7731138-Kidney Glomerulus,
pubmed-meshheading:7731138-Male,
pubmed-meshheading:7731138-Nephrectomy,
pubmed-meshheading:7731138-Platelet-Derived Growth Factor,
pubmed-meshheading:7731138-RNA, Messenger,
pubmed-meshheading:7731138-Rats,
pubmed-meshheading:7731138-Rats, Wistar
|
pubmed:year |
1995
|
pubmed:articleTitle |
Internephron heterogeneity of growth factors and sclerosis--modulation of platelet-derived growth factor by angiotensin II.
|
pubmed:affiliation |
Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|